Bispecific antibodies are an emerging cancer treatment that can attach to two targets at once, making them more precise and powerful than traditional antibodies. One arm of the antibody may bind to cancer cells while the other connects T-cells, directing the immune system to attack tumors even when T-cells don’t naturally recognize them. Some bispecifics block two cancer growth pathways at once, while others remove immune “off switches” to keep T-cells active at the tumor site.
Although highly effective in blood cancers, treating solid tumors is more challenging. Tumors create protective barriers that weaken immune attacks, dense tissue can block antibody penetration, and finding targets that spare healthy cells is difficult.
Despite these hurdles, progress is being made. The FDA has approved two bispecific antibodies for solid tumors, including certain lung and rare eye cancers, and many new designs are in clinical trials, often combined with other therapies to enhance effectiveness.